What is the ICD-10 code for prostate cancer?

The ICD-10-CM code for prostate cancer is C61 when documented without further specification. More specific documentation changes the code — see the scenario table.

Yes — C61 is a billable ICD-10-CM code, but payers expect the most specific code the documentation supports.

ICD-10 Code for prostate cancer

The ICD-10-CM code for prostate cancer is C61 when documented without further specification. HCC RxHCC Malignant neoplasm of the prostate is C61, a single complete code (the prostate has no laterality). Per its Excludes1, malignant neoplasm of the seminal vesicle is C63.7, not C61. A use-additional-code instruction covers hormone sensitivity status (Z19.1-Z19.2) and rising PSA after treatment (R97.21).

C61 is a risk-adjusting diagnosis under CMS-HCC and RxHCC models. Create a free account to see model versions, RAF contribution, and AI-powered HCC suppression analysis.

Create your free account →

Symptom code vs. confirmed diagnosis

C61 is a confirmed-diagnosis code for a documented prostate malignancy, not a screening or PSA-abnormality code. An elevated or rising PSA is reported separately (e.g., R97.21 after treatment) and does not by itself establish C61.

Which Code Should You Use?

C61 ✓ Billable — Malignant neoplasm of prostate

Malignant neoplasm of the prostate.

C63.7 ✓ Billable — Malignant neoplasm of other specified male genital organs

Malignant neoplasm of the seminal vesicle - a different male-genital site, excluded from C61 (Excludes1).

What to Document

That the malignancy is of the prostate itself, not the seminal vesicle (C63.7, per the Excludes1).
Hormone sensitivity status when documented - a use-additional-code instruction covers Z19.1 (hormone sensitive) and Z19.2 (hormone resistant).
Rising PSA following treatment when applicable - reported additionally with R97.21 per the use-additional note.
The histology/morphology as documented by pathology.

Common Documentation Pitfalls

Per the Excludes1, seminal-vesicle malignancy is C63.7, not C61.
Per the use-additional-code note, report hormone sensitivity status (Z19.1-Z19.2) and rising post-treatment PSA (R97.21) in addition when documented.

Instructional Notes for C61

Excludes1

Not coded here. These conditions should NOT be coded together with C61.

malignant neoplasm of seminal vesicle (C63.7)

Use Additional Code

code, if applicable, to identify:
hormone sensitivity status (Z19.1-Z19.2)
rising PSA following treatment for malignant neoplasm of prostate (R97.21)

Also Known As

Official ICD-10-CM Alphabetic Index terms that point to C61:

Adenocarcinoma › duct › unspecified site › male
Carcinoma (malignant) › endometrioid › unspecified site › male
Cystadenocarcinoma › endometrioid › unspecified site › male

Coding Notes

C61 is the single code for a prostate malignancy. Its Excludes1 sends seminal-vesicle cancer to C63.7. A use-additional-code instruction directs reporting hormone sensitivity status (Z19.1-Z19.2) and rising PSA following prostate-cancer treatment (R97.21) when documented.

Prevalence & Statistics

In 2023, an estimated 3,700,086 men in the United States were living with prostate cancer. (NCI SEER Cancer Stat Facts: Prostate Cancer, 2023)